Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ginkgolide C is a diterpene lactone isolated from the leaves of *Ginkgo biloba*. It belongs to the class of organic compounds known as ginkgolides and bilobalides, which are characterized by a rigid hexacyclic structure. Ginkgolide C exhibits multiple biological activities including anticoagulant, neuromodulatory, antioxidative, and anti-apoptotic effects. Mechanistically, it acts as an antagonist at platelet-activating factor (PAF) receptor and inhibits Gamma-aminobutyric acid type A receptor and Glycine receptor alpha 1 subunit. It also increases levels of matrix metalloproteinase 9 (MMP9), cAMP, and cGMP; suppresses thromboxane A2 production; inhibits platelet aggregation; scavenges free radicals; and modulates inflammatory pathways such as MAPK and TLR signaling. These properties have led to research interest in its potential for neuroprotection (e.g., in Alzheimer’s disease), anti-inflammatory action, inhibition of platelet aggregation (anticoagulant effect), and antioxidative stress reduction[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginkgolide-C.